Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. In this study, we...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Nakamura, Koji, Sawada, Kenjiro, Miyamoto, Mayuko, Kinose, Yasuto, Yoshimura, Akihiko, Ishida, Kyoso, Kobayashi, Masaki, Shimizu, Aasa, Nakatsuka, Erika, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363016/
https://ncbi.nlm.nih.gov/pubmed/30774764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26586
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky